Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG) (BSIG-026)

Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CA19-9 and anti-CD3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Ovarian cancer; Pancreatic cancer; Gastric cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CA19-9 & CD3

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Ovarian cancer; Pancreatic cancer; Gastric cancer

Targets

Target 1

CA19-9

Alternative Names

CA19-9; Cancer antigen 19-9; sialylated Lewis (a) antigen; Carbohydrate antigen 19-9

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG) (BSIG-026). Click the button below to contact us or submit your feedback about this product.

Anti-CA19-9 x Anti-CD3 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-026)

Specifications

Targets

Customer Reviews and Q&As